Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Theranos' Correction Plan For Lab Not Enough To Stop CMS Threat

This article was originally published in Clinica

Executive Summary

Beleaguered laboratory firm Theranos Inc. said late last month that it submitted a correction plan to the Center for Medicare and Medicaid Services to remedy the uncorrected testing deficiencies cited from an inspection by the Medicare agency. But the firm's actions so far have not been enough to stop CMS from proposing sanctions on the company in a March 18 letter, including the potential of barring its California location from operating as a clinical laboratory.

Advertisement

Related Content

Theranos Announces New Hires

Topics

Advertisement
UsernamePublicRestriction

Register

MT103351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel